Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
Genedrive PLC (AIM:GDR) CYP2C19-ID Kit adopted for routine clinical use
North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use
Novacyt S.A. (AIM:NCYT) Full year trading update
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Genedrive PLC (AIM:GDR) Genedrive® CYP2C19-ID Kit performance published
Superior performance to laboratory test and alternative available point of care platforms
Novacyt S.A. (AIM: NCYT) London Vet Show: Launch of animal multiplex assays
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Genedrive (AIM:GDR) shares fall 10% following CEO departure
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
Genedrive PLC (AIM: GDR) NICE recommends CYP2C19-ID Kit in final guidance
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
Genedrive PLC (AIM:GDR) Breakthrough Device Designation from the U.S. FDA
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1
Novacyt S.A. (LON:NCYT) Settlement of the dispute with the DHSC
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Genedrive PLC (AIM:GDR) Initial orders of the Genedrive MT-RNR1 Products
Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
Genedrive PLC (AIM:GDR) Proposed REX Retail Offer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the